Last reviewed · How we verify

NCT03337867

Theta-Burst-Stimulation in Recurrent Stroke Recovery

Status unknown Phase 2 Last updated 27 November 2019
What this trial tests

Phase 2 trial testing Magstim Super Rapid2 System in Stroke in 60 participants. Status unknown.

Timeline
11 January 2018
Primary endpoint
1 November 2021
1 November 2021

Quick facts

Lead sponsorUniversity Hospital of Cologne
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposebasic science
Enrollment60
Start date11 January 2018
Primary completion1 November 2021
Estimated completion1 November 2021
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital of Cologne

Who can join

Adults 40 to 90, any sex, with Stroke or Neurorehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims at investigating the effects of intermittent theta-burst stimulation (iTBS) for motor recovery in recurrent stroke patients. Therefore a daily intervention of repetitive transcranial magnetic stimulation over 8 days combined with subsequent physiotherapy is compared to a control condition, sham stimulation combined with subsequent physiotherapy. Motor function, degree of disability and quality of life are examined in order to evaluate the effects of iTBS in the rehabilitation of recurrent stroke patients in the first weeks and after three months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other University Hospital of Cologne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03337867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing